Barcelona-based startup Cebiotex has achieved a significant milestone by developing the first cancer drug currently in clinical trials.
In the world of medical science and technology, this breakthrough represents hope for those facing devastating diseases, such as cancer.
Founded in 2015 as a spin-off from the Hospital Sant Joan de Déu and the Polytechnic University of Catalonia (UPC), Cebiotex has worked tirelessly to bring its innovative drug intended to treat localized solid tumors to production.
The drug is a biodegradable implant containing a chemotherapeutic drug that is highly effective in the treatment.
Cebiotex’s breakthrough in the fight against cancer has been made possible thanks to funding of 154,000 euros granted by Acció’s Innotec line, an initiative dedicated to industrial and experimental research projects.
This investment has enabled the startup to design and manufacture its own equipment for the production of the drug, marking an important step forward in its development and scale-up.
The path to production of this promising drug has involved a Phase 1 clinical trial, which is being conducted at five sarcoma reference hospitals.
The pharmaceutical company will soon start the pilot phase of the new equipment, which represents a crucial step towards the commercialization of the drug.
Cebiotex: first anticancer drug
Cebiotex’s CEO, Joan Bertran, has emphasized the innovation and uniqueness of their pharmaceutical product, highlighting that they have managed to combine the release of a molecule of natural origin with a high chemotherapeutic capacity.
This achievement highlights the startup’s determination and commitment to its fight against cancer and its vision to bring innovative solutions to market.
Cebiotex has marked a before and after in the field of oncology with its first cancer drug.
The focus on localized solid tumors shows the company’s commitment to addressing specific medical needs and providing effective and targeted treatments for those facing this challenging disease.
The success of Cebiotex
It lies in its innovative drug and its multidisciplinary team of experts in diverse fields, from scientists and physicians to engineers and financial and regulatory specialists.
This diversity of talent has enabled the startup to approach cancer from different perspectives and generate unique and promising solutions.
The road to mass production of this drug still presents challenges and steps to be taken, but Cebiotex is optimistic and focused on achieving its ultimate goal.
The pilot tests in collaboration with the pharmaceutical company Prasfarma are a very important step towards the production of clinical batches in clinical phases 2 and 3, and finally, the commercialization of the drug.
